TABLE 1.
Baseline demographics and patient characteristics
|
Tozorakimab+SoC
(n=54) |
SoC
(n=44) |
|
| Age, years | 55.4±12.5 | 58.0±13.9 |
| ≥70 years | 8 (14.8) | 11 (25.0) |
| Male | 37 (68.5) | 29 (65.9) |
| BMI, kg·m−2 | 32.6±8.1 | 33.3±8.5 |
| Smoking status | ||
| Ex-smoker | 26 (48.1) | 16 (37.2) |
| Current smoker | 2 (3.7) | 0 (0.0) |
| Time since onset of symptoms | ||
| <12 days | 38 (70.4) | 37 (84.1) |
| ≥12 days | 16 (29.6) | 7 (15.9) |
| Derived baseline WHO OS score | ||
| Grade 3 | 1 (1.9) | 3 (6.8) |
| Grade 4 | 42 (77.8) | 33 (75.0) |
| Grade 5 | 11 (20.4) | 8 (18.2) |
| NEWS2 score | 4.8±2.2 | 4.0±2.1 |
| Clinical frailty score at baseline | ||
| Very fit | 8 (14.8) | 4 (9.1) |
| Well | 22 (40.7) | 16 (36.4) |
| Managing well | 8 (14.8) | 6 (13.6) |
| Vulnerable | 6 (11.1) | 5 (11.4) |
| Mildly frail | 3 (5.6) | 4 (9.1) |
| Moderately frail | 7 (13.0) | 9 (20.5) |
| Comorbidities at baseline, n # | ||
| ≥1 | 34 (63.0) | 25 (56.8) |
| ≥2 | 21 (38.9) | 13 (29.5) |
| Comorbidity categories # | ||
| Heart disease | 5 (9.3) | 6 (13.6) |
| Diabetes | 22 (40.7) | 13 (29.5) |
| Chronic lung disease | 7 (13.0) | 4 (9.1) |
| Chronic liver disease | 1 (1.9) | 0 (0.0) |
| Asthma | 8 (14.8) | 7 (15.9) |
| HIV | 0 (0.0) | 0 (0.0) |
| Tuberculosis | 0 (0.0) | 1 (2.3) |
| Cancer¶ | 5 (9.6) | 1 (2.4) |
| Hypertension¶ | 15 (28.8) | 13 (31.7) |
| Remdesivir at baseline ¶ | 34 (65.4) | 25 (61.0) |
| Dexamethasone at baseline ¶ | 52 (100.0) | 37 (90.2) |
| Supplemental oxygen at baseline | 53 (98.1) | 41 (93.2) |
| Received COVID-19 vaccine during the study | 13 (24.1) | 4 (9.1) |
Data are presented as mean±sd or n (%). SoC: standard of care; BMI: body mass index; WHO: World Health Organization; OS: ordinal scale; NEWS2: National Early Warning Score 2; COVID-19: coronavirus disease 2019. #: percentage values are based on the safety analysis set; ¶: percentage values are based on 52 patients receiving tozorakimab+SoC and 41 patients receiving SoC.